You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas
WuXi Biologics gains MFDS approval for three Wuxi manufacturing sites
Login
Username:

Password:


Related Headlines

GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation

Boehringer Ingelheim's survodutide phase 3 data show significant weight loss in obesity trial

Xcovery and EVERSANA partner for US commmercialisation of lung cancer drug Ensacove

Jazz Pharmaceuticals reports FDA acceptance and Priority Review of sBLA for Ziihera (zanidatamab-hrii) combinations in first-line HER2+ locally advanced or metastatic GEA

Novartis secures European approval for remibrutinib in chronic spontaneous urticaria

GSK secures US and EU fast-track designations for efimosfermin in MASH

Veradermics reports positive Phase 2/3 results for oral VDPHL01 in pattern hair loss treatment

Cantargia reports early remission data from nadunolimab trial in MDS and AML

AOTI reports strong real-world outcomes for TWO2 wound therapy

WuXi Biologics announces structural completion and key equipment arrival at Chengdu microbial manufacturing site

HanchorBio chooses Bloomberg to enhance strategic intelligence across drug development and global biopharma

Ascletis completes enrolment for US Phase II study of ASC30 in diabetes

Servier completes Day One Biopharmaceuticals acquisition

Cipla's AB-rated Ventolin HFA generic receives US FDA approval

Apotex and Cumberland Pharmaceuticals to integrate their US branded businesses

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026